Vysis wins FDA approval for test identifying more aggressive form of breast cancer
This article was originally published in Clinica
The FDA has approved Vysis' gene-based test for identifying whether a breast cancer patient has a more aggressive and often fatal form of the disease.
You may also be interested in...
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.